Slack pursued an unusual direct listing, meaning it did not have banks underwrite the offering.CNBC Disruptor 50read more
President Trump says Iran may not have intentionally downed an unmanned U.S. surveillance drone.Politicsread more
Slack's CEO said that the company didn't want to go public via an IPO so that it could be as transparent and accessible as possible.Deals and IPOsread more
Oil jumped as much as 6% on Thursday after Iran shot down a U.S. military drone, prompting President Trump to blast Tehran on Twitter.Energy Commoditiesread more
If Facebook cut corners in something as basic as the branding of its nascent crypto efforts, this dispute could give ammunition to its many critics.Financeread more
CNBC analysis using Kensho found that Disney, Verizon and Home Depot were some of the best performing Dow stocks in declining-rate environments.Investingread more
For doubters thinking the rally is just a last gasp of the decade-long bull market, chart analysts are here to prove them wrong.Marketsread more
Notorious "pharma bro" Martin Shkreli has reached a settlement with his former biopharmaceutical company Retrophin just weeks ago after he sued two company directors and its...Biotech and Pharmaceuticalsread more
"The slowdown in the global economy is reaching this shore," veteran trader Art Cashin says.Economyread more
Slack's public market debut on Thursday will generate billions for venture firm Accel and healthy returns for Andreessen Horowitz and Social CapitalTechnologyread more
JetBlue is ordering the longest-range Airbus jets to expand service to more European cities.Airlinesread more
Drugmaker AstraZeneca has agreed to pay $110 million to settle two lawsuits brought by the state of Texas claiming that it fraudulently marketed the antipsychotic drug Seroquel and Crestor for high cholesterol.
The largest settlement, totaling $90 million, resolves allegations the drugmaker encouraged doctors to use Seroquel for unapproved uses. A second settlement for $20 million covers allegations it misrepresented the benefits of Crestor.
Texas Attorney General Ken Paxton, announcing the settlements, said the alleged actions were "especially disturbing because the well-being of children and the integrity of the state hospital system were jeopardized".
Texas had sought $5 billion under the lawsuits, claiming the company had falsely and misleadingly marketed the two drugs in violation of the Texas Medicaid Fraud Prevention Act.
AstraZeneca has denied any wrongdoing.
"AstraZeneca makes no concessions or admissions of fault in the settlement agreements," the group said in a statement.
"While we deny the allegations, it is in the best interests of the company to resolve these matters and to move forward with our business of discovering and developing important, life-changing medicines – while avoiding the delay, uncertainty, and expense of protracted litigation."